close

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutics based on RNA interference (RNAi). The company's lead RNAi therapeutic program includes ALN-RSV01, a phase II clinical trial product for the treatment of respiratory syncytial virus (RSV) infection. It develops RNAi therapeutics for the treatment of liver cancers, hypercholesterolemia, Huntington's disease, and transthyretin amyloidosis. The company has collaboration and license agreements with Isis Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited for the discovery, development, and commercialization of RNAi therapeutics; with Novartis Pharma AG to discover, develop, commercialize, and manufacture compounds that function through the mechanism of RNAi; and with Biogen Idec Inc. for the discovery and development of therapeutics based on RNAi for the treatment of progressive multifocal leukoencephalopathy. It also holds license and collaboration agreements with Medtronic, Inc. to develop therapeutic products for the treatment of neurodegenerative disorders; with Kyowa Hakko for the development and commercialization of ALN-RSV01; with Cubist Pharmaceuticals, Inc. to develop and commercialize therapeutic products for the treatment of RSV; and with F. Hoffmann-La Roche Ltd. to develop and commercialize therapeutics in the areas of oncology, respiratory, metabolic, and liver diseases. The company's joint venture, Regulus Therapeutics LLC, focuses on the discovery, development, and commercialization of microRNA therapeutic that targets miR-122 for the treatment of hepatitis C virus infection. In addition, it grants its intellectual property rights licenses to biotechnology companies for the development and commercialization of RNAi therapeutics; and to research companies that commercialize RNAi reagents or services under its research product licenses. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	11.79
Volume	158025
Volume Avg	489587
52 Week High	13.75
52 Week Low	5.88
PE	N/A
PE (group average)	39
EPS Year	-1.36
EPS change Q/Q	-137.5%
EPS change Q/Q Yr ago	-31.03%
EPS change Q/Q next Q est	-40.74%
EPS change Y/Y	-11.61%
REV change Q/Q	-1.42%
REV change Q/Q Yr ago	-15.04%
EPS next Q est	-0.27
EPS next Y est	-2.27
Divident Annual	0.00
Dividend Yield	0%